Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Mucopolysaccharidoses: Clinical features and diagnosis

Simon Jones, MD
Robert Wynn, MD, MRCP, FRCPath
Section Editors
Sihoun Hahn, MD, PhD
Marc C Patterson, MD, FRACP
Deputy Editor
Elizabeth TePas, MD, MS


The mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs), previously known as mucopolysaccharides [1-3]. Fragments of partially degraded GAGs accumulate in the lysosomes, resulting in cellular dysfunction and clinical abnormalities. The clinical features and diagnosis of the MPS are reviewed here. The management of these disorders and associated complications are discussed separately. (See "Mucopolysaccharidoses: Complications".)


The MPS are rare conditions, with an estimated total incidence of all types of MPS of approximately 1 in 20,000 live births [4-6].


Glycosaminoglycans (GAGs) are large, complex polymers of linear, repeating sulfated acidic and amino sugar disaccharide units attached to a protein core. They are widely distributed in many tissues, where they play important roles. As examples, they are components of the ground substance of bone and cartilage, lubricant in joint fluid, and the surface coating that initially binds growth factors to cells.

The metabolic recycling of GAGs requires the stepwise degradation of the terminal sulfate, acidic, and amino sugar residues by a series of lysosomal enzymes. The deficiency of one of these enzymes blocks degradation of the substrate and results in a specific disorder. The clinical phenotype of the disorder depends upon both the amount of residual enzyme activity and the distribution and turnover of the substrate affected by the deficiency, rather than the distribution of the enzyme.


All of the MPS are autosomal recessive disorders, with the exception of MPS II, which is X linked. The affected genes and chromosomal locations are shown in the table (table 1).

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 12, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Cimaz R, La Torre F. Mucopolysaccharidoses. Curr Rheumatol Rep 2014; 16:389.
  2. Mitrovic S, Gouze H, Gossec L, et al. Mucopolysaccharidoses seen in adults in rheumatology. Joint Bone Spine 2017.
  3. Jones S, Wijburg F. Mucopolysaccharidoses, oligosaccharidoses and sialic acid disorders. In: Inborn Metabolic Diseases: Diagnosis and Treatment, 6th ed., Saudubray JM, Baumgarter MR, Walter J (Eds), Springer, Berlin 2016. p.577.
  4. Caruso RC, Kaiser-Kupfer MI, Muenzer J, et al. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology 1986; 93:1612.
  5. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999; 105:151.
  6. Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab 2013; 110:42.
  7. Scott HS, Bunge S, Gal A, et al. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 1995; 6:288.
  8. Wappner RS. Lysosomal storage disorders. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams & Wilkins, Philadelphia 2006. p.2199.
  9. White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 Suppl 5:v26.
  10. Morishita K, Petty RE. Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 Suppl 5:v19.
  11. Neufeld EF, Muenzer J. The metabolic and molecular bases of inherited disease, Scriver C, Beaudet AL, Valle D, Sly W (Eds), McGraw-Hill, New York 2001. p.3421.
  12. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167:267.
  13. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120:405.
  14. Instability of the upper cervical spine. Skeletal Dysplasia Group. Arch Dis Child 1989; 64:283.
  15. Schmidt H, Ullrich K, von Lengerke HJ, et al. Radiological findings in patients with mucopolysaccharidosis I H/S (Hurler-Scheie syndrome). Pediatr Radiol 1987; 17:409.
  16. Scott HS, Ashton LJ, Eyre HJ, et al. Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3. Am J Hum Genet 1990; 47:802.
  17. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr 2005; 94:872.
  18. D'Aco K, Underhill L, Rangachari L, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr 2012; 171:911.
  19. Malm G, Lund AM, Månsson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr 2008; 97:1577.
  20. Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 1995; 84:337.
  21. Stevenson RE, Howell RR, McKusick VA, et al. The iduronidase-deficient mucopolysaccharidoses: clinical and roentgenorgraphic features. Pediatrics 1976; 57:111.
  22. Muenzer J. Mucopolysaccharidoses. Adv Pediatr 1986; 33:269.
  23. Alroy J, Haskins M, Birk DE. Altered corneal stromal matrix organization is associated with mucopolysaccharidosis I, III and VI. Exp Eye Res 1999; 68:523.
  24. Summers CG, Purple RL, Krivit W, et al. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. Ophthalmology 1989; 96:977.
  25. Bredenkamp JK, Smith ME, Dudley JP, et al. Otolaryngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Laryngol 1992; 101:472.
  26. Ruckenstein MJ, Macdonald RE, Clarke JT, Forte V. The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review. J Otolaryngol 1991; 20:177.
  27. Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine (Baltimore) 1988; 67:209.
  28. Wippermann CF, Beck M, Schranz D, et al. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 1995; 154:98.
  29. Braunlin EA, Hunter DW, Krivit W, et al. Evaluation of coronary artery disease in the Hurler syndrome by angiography. Am J Cardiol 1992; 69:1487.
  30. Taylor DB, Blaser SI, Burrows PE, et al. Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: imaging findings. AJR Am J Roentgenol 1991; 157:819.
  31. Brosius FC 3rd, Roberts WC. Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol 1981; 47:649.
  32. Nelson J, Shields MD, Mulholland HC. Cardiovascular studies in the mucopolysaccharidoses. J Med Genet 1990; 27:94.
  33. Haddad FS, Jones DH, Vellodi A, et al. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br 1997; 79:576.
  34. Kaufman HH, Rosenberg HS, Scott CI, et al. Cervical myelopathy due to dural compression in mucopolysaccharidosis. Surg Neurol 1982; 17:404.
  35. Roubicek M, Gehler J, Spranger J. The clinical spectrum of alpha-L-iduronidase deficiency. Am J Med Genet 1985; 20:471.
  36. Masuda H, Morishita Y, Taira A, Kuriyama M. Aortic stenosis associated with Scheie's syndrome. Report of successful valve replacement. Chest 1993; 103:968.
  37. Butman SM, Karl L, Copeland JG. Combined aortic and mitral valve replacement in an adult with Scheie's disease. Chest 1989; 96:209.
  38. Fischer TA, Lehr HA, Nixdorff U, Meyer J. Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome). Heart 1999; 81:97.
  39. Hopwood JJ, Bunge S, Morris CP, et al. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mutat 1993; 2:435.
  40. Brusius-Facchin AC, De Souza CF, Schwartz IV, et al. Severe phenotype in MPS II patients associated with a large deletion including contiguous genes. Am J Med Genet A 2012; 158A:1055.
  41. Tuschl K, Gal A, Paschke E, et al. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005; 32:270.
  42. Sukegawa K, Matsuzaki T, Fukuda S, et al. Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation. Clin Genet 1998; 53:96.
  43. Clarke JT, Greer WL, Strasberg PM, et al. Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am J Hum Genet 1991; 49:289.
  44. Winchester B, Young E, Geddes S, et al. Female twin with Hunter disease due to nonrandom inactivation of the X-chromosome: a consequence of twinning. Am J Med Genet 1992; 44:834.
  45. Mossman J, Blunt S, Stephens R, et al. Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene. Arch Dis Child 1983; 58:911.
  46. Broadhead DM, Kirk JM, Burt AJ, et al. Full expression of Hunter's disease in a female with an X-chromosome deletion leading to non-random inactivation. Clin Genet 1986; 30:392.
  47. Sukegawa K, Song XQ, Masuno M, et al. Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Hum Mutat 1997; 10:361.
  48. Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr 2012; 171:631.
  49. Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in Hunter syndrome. J Pediatr 2011; 159:327.
  50. Demitsu T, Kakurai M, Okubo Y, et al. Skin eruption as the presenting sign of Hunter syndrome IIB. Clin Exp Dermatol 1999; 24:179.
  51. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983; 25:481.
  52. Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr 2011; 159:320.
  53. Scott HS, Blanch L, Guo XH, et al. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet 1995; 11:465.
  54. Zhao HG, Li HH, Bach G, et al. The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci U S A 1996; 93:6101.
  55. Fan X, Zhang H, Zhang S, et al. Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C). Am J Hum Genet 2006; 79:738.
  56. Hrebícek M, Mrázová L, Seyrantepe V, et al. Mutations in TMEM76* cause mucopolysaccharidosis IIIC (Sanfilippo C syndrome). Am J Hum Genet 2006; 79:807.
  57. Robertson DA, Callen DF, Baker EG, et al. Chromosomal localization of the gene for human glucosamine-6-sulphatase to 12q14. Hum Genet 1988; 79:175.
  58. Malm G, Månsson JE. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr 2010; 99:1253.
  59. Shapiro EG, Nestrasil I, Delaney KA, et al. A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA. J Pediatr 2016; 170:278.
  60. White KK, Karol LA, White DR, Hale S. Musculoskeletal manifestations of Sanfilippo Syndrome (mucopolysaccharidosis type III). J Pediatr Orthop 2011; 31:594.
  61. Nidiffer FD, Kelly TE. Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. J Ment Defic Res 1983; 27 (Pt 3):185.
  62. Wraith JE, Danks DM, Rogers JG. Mild Sanfilippo syndrome: a further cause of hyperactivity and behavioural disturbance. Med J Aust 1987; 147:450.
  63. Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child 1995; 73:77.
  64. Meyer A, Kossow K, Gal A, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2007; 120:e1255.
  65. Colville GA, Watters JP, Yule W, Bax M. Sleep problems in children with Sanfilippo syndrome. Dev Med Child Neurol 1996; 38:538.
  66. van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 1981; 20:152.
  67. Baker E, Guo XH, Orsborn AM, et al. The morquio A syndrome (mucopolysaccharidosis IVA) gene maps to 16q24.3. Am J Hum Genet 1993; 52:96.
  68. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 1996; 19:357.
  69. Mikles M, Stanton RP. A review of Morquio syndrome. Am J Orthop (Belle Mead NJ) 1997; 26:533.
  70. Nelson J, Broadhead D, Mossman J. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part I: Clinical and biochemical findings. Clin Genet 1988; 33:111.
  71. Holzgreve W, Gröbe H, von Figura K, et al. Morquio syndrome: clinical findings in 11 patients with MPS IVA and 2 patients with MPS IVB. Hum Genet 1981; 57:360.
  72. Stevens JM, Kendall BE, Crockard HA, Ransford A. The odontoid process in Morquio-Brailsford's disease. The effects of occipitocervical fusion. J Bone Joint Surg Br 1991; 73:851.
  73. Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia. Clin Genet 1988; 33:126.
  74. Lipson SJ. Dysplasia of the odontoid process in Morquio's syndrome causing quadriparesis. J Bone Joint Surg Am 1977; 59:340.
  75. Hughes DG, Chadderton RD, Cowie RA, et al. MRI of the brain and craniocervical junction in Morquio's disease. Neuroradiology 1997; 39:381.
  76. Fidzianska E, Abramowicz T, Czartoryska B, et al. Assignment of the gene for human arylsulfatase B, ARSB, to chromosome region 5p11----5qter. Cytogenet Cell Genet 1984; 38:150.
  77. Litjens T, Hopwood JJ. Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 2001; 18:282.
  78. Spranger JW, Koch F, McKusick VA, et al. Mucopolysaccharidosis VI (Maroteaux-Lamy's disease). Helv Paediatr Acta 1970; 25:337.
  79. Tan CT, Schaff HV, Miller FA Jr, et al. Valvular heart disease in four patients with Maroteaux-Lamy syndrome. Circulation 1992; 85:188.
  80. Hayflick S, Rowe S, Kavanaugh-McHugh A, et al. Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VI. J Pediatr 1992; 120:269.
  81. Miller G, Partridge A. Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure. Pediatr Cardiol 1983; 4:61.
  82. John A, Fagondes S, Schwartz I, et al. Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI. Am J Med Genet A 2011; 155A:1546.
  83. Sheridan M, Chaseling R, Johnston IH. Hydrocephalus, lumbar canal stenosis and Maroteaux-Lamy syndrome (mucopolysaccharidosis type 6). Case report. J Neurosurg Sci 1992; 36:215.
  84. Thorne JA, Javadpour M, Hughes DG, et al. Craniovertebral abnormalities in Type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 2001; 48:849.
  85. Young R, Kleinman G, Ojemann RG, et al. Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings. Ann Neurol 1980; 8:336.
  86. Schwartz CE, Stanislovitis P, Phelan MC, et al. Deletion mapping of plasminogen activator inhibitor, type I (PLANH1) and beta-glucuronidase (GUSB) in 7q21----q22. Cytogenet Cell Genet 1991; 56:152.
  87. Beaudet AL, DiFerrante NM, Ferry GD, et al. Variation in the phenotypic expression of beta-glucuronidase deficiency. J Pediatr 1975; 86:388.
  88. Danes BS, Degnan M. Different clinical and biochemical phenotypes associated with b-glucuronidase deficiency. Birth Def Orig Art Ser 1974; X:251.
  89. Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 1973; 82:249.
  90. Pizzutillo PD, Osterkamp JA, Scott CI Jr, Lee MS. Atlantoaxial instability in mucopolysaccharidosis type VII. J Pediatr Orthop 1989; 9:76.
  91. Lee JE, Falk RE, Ng WG, Donnell GN. Beta-glucuronidase deficiency. A heterogeneous mucopolysaccharidosis. Am J Dis Child 1985; 139:57.
  92. Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr 1999; 46:409.
  93. Vervoort R, Islam MR, Sly WS, et al. Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII. Am J Hum Genet 1996; 58:457.
  94. de Kremer RD, Givogri I, Argaraña CE, et al. Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a chronic variant with an oligosymptomatic severe skeletal dysplasia. Am J Med Genet 1992; 44:145.
  95. Natowicz MR, Short MP, Wang Y, et al. Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med 1996; 335:1029.
  96. Csóka AB, Frost GI, Heng HH, et al. The hyaluronidase gene HYAL1 maps to chromosome 3p21.2-p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor locus. Genomics 1998; 48:63.
  97. Imundo L, Leduc CA, Guha S, et al. A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inherit Metab Dis 2011; 34:1013.
  98. Martin DC, Atmuri V, Hemming RJ, et al. A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis. Hum Mol Genet 2008; 17:1904.
  99. Stone JE. Urine analysis in the diagnosis of mucopolysaccharide disorders. Ann Clin Biochem 1998; 35 ( Pt 2):207.
  100. Brimble A, Pennock C, Stone J. Results of a quality assurance exercise for urinary glycosaminoglycan excretion. Ann Clin Biochem 1990; 27 ( Pt 2):133.
  101. Pennock CA. A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses. J Clin Pathol 1976; 29:111.
  102. Longdon K, Pennock CA. Abnormal keratan sulphate excretion. Ann Clin Biochem 1979; 16:152.
  103. Linker A, Evans LR, Langer LO. Morquio's disease and mucopolysaccharide excretion. J Pediatr 1970; 77:1039.
  104. Blanchard S, Sadilek M, Scott CR, et al. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem 2008; 54:2067.
  105. Wang D, Wood T, Sadilek M, et al. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem 2007; 53:137.
  106. Dean CJ, Bockmann MR, Hopwood JJ, et al. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin Chem 2006; 52:643.
  107. Fensom AH, Benson PF. Recent advances in the prenatal diagnosis of the mucopolysaccharidoses. Prenat Diagn 1994; 14:1.
  108. Cleary MA, Wraith JE. Antenatal diagnosis of inborn errors of metabolism. Arch Dis Child 1991; 66:816.
  109. Bunge S, Steglich C, Lorenz P, et al. Prenatal diagnosis and carrier detection in mucopolysaccharidosis type II by mutation analysis. A 47,XXY male heterozygous for a missense point mutation. Prenat Diagn 1994; 14:777.
  110. Burin MG, Ribeiro E, Mari Jd, et al. Prenatal diagnosis of mucopolysaccharidosis VI by enzyme assay in a dried spot of fetal blood: a pioneering case report. Prenat Diagn 2010; 30:89.
  111. Clarke LA, Atherton AM, Burton BK, et al. Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management. J Pediatr 2017; 182:363.
  112. Groener JE, de Graaf FL, Poorthuis BJ, Kanhai HH. Prenatal diagnosis of lysosomal storage diseases using fetal blood. Prenat Diagn 1999; 19:930.